In this interview, Jon Haulenbeek (Bristol-Myers Squibb; NJ, USA) discusses his role as a Group Leader running the Reagent Center of Excellence in the Translational Medicine Division.
In this interview, Hanna Ritzén (Mercodia; Uppsala, Sweden) provides an insight into her recent article on classification of commercial LBA kits for biomarkers, and why this area of bioanalysis is important.
John Chappell (Gyros Protein Technologies; Uppsala Sweden) discusses features of Gyrolab technology that make it a must-have in biotherapeutics development and manufacturing.
Complete our short survey on ligand binding assays and be the first to receive our informative infographic collated from the survey results.
In this interview, Wenying Jian (Janssen Research & Development, Johnson & Johnson; NY, USA) describes the basic principles of hybrid LBA/LC–MS and how this technique can be used to quantify proteins.
Tanja Jarhede, Senior Scientist, Mercodia AB, (Uppsala, Sweden) 1. Could you introduce yourself and explain…
Evaluation of therapeutic antibody performance with multiple nanolitre-scale immunoassays in a single run
Find out more about the evaluation of therapeutic antibody performance with multiple nanolitre-scale immunoassays in a single run in this poster from Gyros Protein Technologies.
Scientists at Pfizer have reported a retrospective study of pharmacokinetics (PK) data that highlights the…
Authors Frida Henningson Johnson, Hampus Elofsson, Esrat Qamrul-Ehsan and Hanna Ritzén, Mercodia AB (Uppsala, Sweden)…
In this interview, Stephanie Traub (Cancer Research UK; London, UK) discusses her work as a biomarker specialist and the challenges she faces when developing biomarker strategies.